Pan-cancer Analysis of TP53 Expression: Prognostic Significance and Identification of Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma
Journal of Biochemical and Clinical Genetics · 2025
DOI: 10.24911/jbcgenetics.11-2208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Clinical Genetics, 2025. Verfasst von Amna Atia und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (LIHC) is a common and aggressive liver malignancy, often diagnosed at advanced stages. Dysregulation of the TP53 tumor suppressor gene critical for cell cycle control, apoptosis, and genomic stabilityis frequently observed in LIHC; however, its prognostic value remains uncertain.
Objectives
To investigate TP53 expression levels, prognostic relevance, and molecular interactions in LIHC within a broader pan-cancer context.
Methods
Publicly available datasets from TCGA and GEO were analyzed. TP53 differential expression was evaluated using TIMER 2.0, GEPIA, and UALCAN. Survival analysis was performed via Kaplan-Meier Plotter, GEPIA, and UALCAN. Genomic alterations were assessed through cBioPortal. Gene expression validation was conducted using GEO2R and ggplot2. Protein-protein interaction networks were constructed using STRING and GeneMANIA.
Results
TP53 mRNA expression was significantly elevated in LIHC tumor tissues compared to normal liver tissues (p < 0.05). Promoter hypo-methylation was noted in tumor samples, potentially contributing to this up-regulation. Survival analysis revealed conflicting findings: Kaplan-Meier Plotter associated high TP53 expression with better prognosis (HR = 0.65, p = 0.029), whereas GEPIA and UALCAN linked high expression with poorer outcomes. Furthermore, TP53 expression positively correlated with immune cell infiltration and advanced clinical stage, suggesting a complex role in tumor progression.
Conclusion
TP53 demonstrates a dual, context-dependent role in LIHC, acting as both a tumor suppressor and potential oncogenic driver. Its variable expression patterns and inconsistent prognostic associations highlight its potential as a diagnostic and prognostic biomarker and support the need for further functional and clinical validation.
Zitieren
APA
Atia, A., & Alfaki, M. (2025). Pan-cancer Analysis of TP53 Expression: Prognostic Significance and Identification of Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Journal of Biochemical and Clinical Genetics. https://doi.org/10.24911/jbcgenetics.11-2208
Vancouver
Atia A, Alfaki M. Pan-cancer Analysis of TP53 Expression: Prognostic Significance and Identification of Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Journal of Biochemical and Clinical Genetics. 2025. doi:10.24911/jbcgenetics.11-2208
BibTeX
@article{Atia2025,
author = {Atia, Amna and Alfaki, Mohamed},
title = {Pan-cancer Analysis of TP53 Expression: Prognostic Significance and Identification of Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma},
journal = {Journal of Biochemical and Clinical Genetics},
year = {2025},
doi = {10.24911/jbcgenetics.11-2208}
}
EUVIMED